Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2016

01.06.2016 | Preclinical study

Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation

verfasst von: Gabriela Szalayova, Aleksandra Ogrodnik, Brianna Spencer, Jacqueline Wade, Janice Bunn, Abiy Ambaye, Ted James, Mercedes Rincon

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic inflammation is known to facilitate cancer progression and metastasis. Less is known about the effect of acute inflammation within the tumor microenvironment, resulting from standard invasive procedures. Recent studies in mouse models have shown that the acute inflammatory response triggered by a biopsy in mammary cancer increases the frequency of distal metastases. Although tumor biopsies are part of the standard clinical practice in breast cancer diagnosis, no studies have reported their effect on inflammatory response. The objective of this study is to (1) determine whether core needle biopsies in breast cancer patients trigger an inflammatory response, (2) characterize the type of inflammatory response present, and (3) evaluate the potential effect of any acute inflammatory response on residual tumor cells. The biopsy wound site was identified in the primary tumor resection tissue samples from breast cancer patients. The inflammatory response in areas adjacent (i.e., immediately around previous biopsy site) and distant to the wound biopsy was investigated by histology and immunohistochemistry analysis. Proliferation of tumor cells was also assayed. We demonstrate that diagnostic core needle biopsies trigger a selective recruitment of inflammatory cells at the site of the biopsy, and they persist for extended periods of time. While macrophages were part of the inflammatory response, an unexpected accumulation of eosinophils at the edge of the biopsy wound was also identified. Importantly, we show that biopsy causes an increase in the proliferation rate of tumor cells located in the area adjacent to the biopsy wound. Diagnostic core needle biopsies in breast cancer patients do induce a unique acute inflammatory response within the tumor microenvironment and have an effect on the surrounding tumor cells. Therefore, biopsy-induced inflammation could have an impact on residual tumor cell progression and/or metastasis in human breast cancer. These findings may carry relevance in the clinical management of breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al (2015) SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda. http://www.seercancergov/csr/1975_2012/ based on November 2014 SEER data submission, posted to the SEER web site, April 2015 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al (2015) SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda. http://​www.​seercancergov/​csr/​1975_​2012/​ based on November 2014 SEER data submission, posted to the SEER web site, April 2015
2.
3.
Zurück zum Zitat Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125:3347–3355CrossRefPubMed Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125:3347–3355CrossRefPubMed
5.
Zurück zum Zitat Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26:2350–2357CrossRefPubMed Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26:2350–2357CrossRefPubMed
6.
Zurück zum Zitat Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E et al (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33:335–351CrossRefPubMedPubMedCentral Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E et al (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33:335–351CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108CrossRefPubMed Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108CrossRefPubMed
8.
Zurück zum Zitat Multhoff G, Molls M, Radons J (2011) Chronic inflammation in cancer development. Front Immunol 2:98PubMed Multhoff G, Molls M, Radons J (2011) Chronic inflammation in cancer development. Front Immunol 2:98PubMed
10.
Zurück zum Zitat Szalayova G, James TA, Rincon M (2015) A framework for the role of acute inflammation in tumor progression. Breast Cancer Res Treat 151:235–238CrossRefPubMed Szalayova G, James TA, Rincon M (2015) A framework for the role of acute inflammation in tumor progression. Breast Cancer Res Treat 151:235–238CrossRefPubMed
11.
Zurück zum Zitat Arnold KM, Opdenaker LM, Flynn D, Sims-Mourtada J (2015) Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastas 8:1–13 Arnold KM, Opdenaker LM, Flynn D, Sims-Mourtada J (2015) Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastas 8:1–13
12.
Zurück zum Zitat Ceelen W, Pattyn P, Mareel M (2014) Surgery, wound healing, and metastasis: recent insights and clinical implications. Crit Rev Oncol Hematol 89:16–26CrossRefPubMed Ceelen W, Pattyn P, Mareel M (2014) Surgery, wound healing, and metastasis: recent insights and clinical implications. Crit Rev Oncol Hematol 89:16–26CrossRefPubMed
13.
Zurück zum Zitat Fitzal F, Sporn EP, Draxler W, Mittlbock M, Taucher S, Rudas M, Riedl O, Helbich TH, Jakesz R, Gnant M (2006) Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. Breast Cancer Res Treat 97:9–15CrossRefPubMed Fitzal F, Sporn EP, Draxler W, Mittlbock M, Taucher S, Rudas M, Riedl O, Helbich TH, Jakesz R, Gnant M (2006) Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. Breast Cancer Res Treat 97:9–15CrossRefPubMed
14.
Zurück zum Zitat Chen AM, Haffty BG, Lee CH (2002) Local recurrence of breast cancer after breast conservation therapy in patients examined by means of stereotactic core-needle biopsy. Radiology 225:707–712CrossRefPubMed Chen AM, Haffty BG, Lee CH (2002) Local recurrence of breast cancer after breast conservation therapy in patients examined by means of stereotactic core-needle biopsy. Radiology 225:707–712CrossRefPubMed
15.
Zurück zum Zitat King TA, Hayes DH, Cederbom GJ, Champaign JL, Smetherman DH, Farr GH, Bolton JS, Fuhrman GM (2001) Biopsy technique has no impact on local recurrence after breast-conserving therapy. Breast J 7:19–24CrossRefPubMed King TA, Hayes DH, Cederbom GJ, Champaign JL, Smetherman DH, Farr GH, Bolton JS, Fuhrman GM (2001) Biopsy technique has no impact on local recurrence after breast-conserving therapy. Breast J 7:19–24CrossRefPubMed
16.
Zurück zum Zitat Hoorntje LE, Schipper ME, Kaya A, Verkooijen HM, Klinkenbijl JG, Borel Rinkes IH (2004) Tumour cell displacement after 14G breast biopsy. Eur J Surg Oncol 30:520–525CrossRefPubMed Hoorntje LE, Schipper ME, Kaya A, Verkooijen HM, Klinkenbijl JG, Borel Rinkes IH (2004) Tumour cell displacement after 14G breast biopsy. Eur J Surg Oncol 30:520–525CrossRefPubMed
17.
Zurück zum Zitat Thurfjell MG, Jansson T, Nordgren H, Bergh J, Lindgren A, Thurfjell E (2000) Local breast cancer recurrence caused by mammographically guided punctures. Acta Radiol 41:435–440CrossRefPubMed Thurfjell MG, Jansson T, Nordgren H, Bergh J, Lindgren A, Thurfjell E (2000) Local breast cancer recurrence caused by mammographically guided punctures. Acta Radiol 41:435–440CrossRefPubMed
18.
Zurück zum Zitat Chao C, Torosian MH, Boraas MC, Sigurdson ER, Hoffman JP, Eisenberg BL, Fowble B (2001) Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature. Breast J 7:124–127CrossRefPubMed Chao C, Torosian MH, Boraas MC, Sigurdson ER, Hoffman JP, Eisenberg BL, Fowble B (2001) Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature. Breast J 7:124–127CrossRefPubMed
19.
Zurück zum Zitat Hobson J, Gummadidala P, Silverstrim B, Grier D, Bunn J, James T, Rincon M (2013) Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis. Breast Cancer Res Treat 139:391–401CrossRefPubMedPubMedCentral Hobson J, Gummadidala P, Silverstrim B, Grier D, Bunn J, James T, Rincon M (2013) Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis. Breast Cancer Res Treat 139:391–401CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625–4629PubMed Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625–4629PubMed
22.
Zurück zum Zitat Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612CrossRefPubMed Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612CrossRefPubMed
23.
Zurück zum Zitat Ham M, Moon A (2013) Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharmacal Res 36:1419–1431CrossRef Ham M, Moon A (2013) Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharmacal Res 36:1419–1431CrossRef
24.
Zurück zum Zitat Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A et al (2015) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology 18(4):557–564CrossRefPubMed Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A et al (2015) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology 18(4):557–564CrossRefPubMed
25.
Zurück zum Zitat von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A (2015) An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma. Clin Cancer Res 21:1843–1850CrossRef von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A (2015) An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma. Clin Cancer Res 21:1843–1850CrossRef
26.
Zurück zum Zitat Zhang YJ, Wei L, Li J, Zheng YQ, Li XR (2013) Status quo and development trend of breast biopsy technology. Gland Surg 2:15–24PubMedPubMedCentral Zhang YJ, Wei L, Li J, Zheng YQ, Li XR (2013) Status quo and development trend of breast biopsy technology. Gland Surg 2:15–24PubMedPubMedCentral
27.
Zurück zum Zitat Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224CrossRefPubMed Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224CrossRefPubMed
28.
Zurück zum Zitat Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103:12493–12498CrossRefPubMedPubMedCentral Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103:12493–12498CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Homig-Holzel C et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507:109–113CrossRefPubMed Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Homig-Holzel C et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507:109–113CrossRefPubMed
30.
Zurück zum Zitat Ravin KA, Loy M (2016) The eosinophil in infection. Clin Rev Allerg Immunol 50(2):214–227 Ravin KA, Loy M (2016) The eosinophil in infection. Clin Rev Allerg Immunol 50(2):214–227
31.
Zurück zum Zitat Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allerg Clin Immunol 125:S73–S80CrossRef Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allerg Clin Immunol 125:S73–S80CrossRef
33.
Zurück zum Zitat Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, Blomqvist C (2007) Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 7:165CrossRefPubMedPubMedCentral Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, Blomqvist C (2007) Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 7:165CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Dethlefsen C, Hojfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138:657–664CrossRefPubMed Dethlefsen C, Hojfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138:657–664CrossRefPubMed
35.
Zurück zum Zitat Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMedPubMedCentral Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMedPubMedCentral
36.
Zurück zum Zitat Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61:8851–8858PubMed Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61:8851–8858PubMed
Metadaten
Titel
Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation
verfasst von
Gabriela Szalayova
Aleksandra Ogrodnik
Brianna Spencer
Jacqueline Wade
Janice Bunn
Abiy Ambaye
Ted James
Mercedes Rincon
Publikationsdatum
01.06.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3839-3

Weitere Artikel der Ausgabe 3/2016

Breast Cancer Research and Treatment 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.